Skip to main content
Quest Diagnostics

Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association With COVID-19 Pathology and Vaccine Protection

Microfluidic immuno-serolomic assay reveals systems level association with COVID-19 pathology and vaccine protection

Authors: Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R

Small Methods. 2023 Jun 13;e2300594. doi: 10.1002/smtd.202300594. Online ahead of print.

Specialties: Infectious disease, COVID-19

Related content

Conference Presentation
SARS-CoV-2 IGM Detection in Relation To Reactivity In 4 SARS-Cov-2 IGG Assays
Publication
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
Publication
Risk of and duration of protection from SARS CoV 2 reinfection assessed with real world data
Publication
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
Publication
Microfluidic immuno-serolomic assay reveals systems level association with COVID-19 pathology and vaccine protection

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.